Last updated on February 2018

IAI Versus Sham as Prophylaxis Against Conversion to Neovascular AMD


Brief description of study

This is a prospective, single-blind, randomized study to evaluate intravitreal aflibercept injection (IAI) versus sham as prophylaxis against conversion to neovascular age-related macular degeneration (AMD) in "high-risk" subjects.

Detailed Study Description

128 subjects will be enrolled in the trial and randomized in a 1:1 ratio to receive either IAI every three months for 24 months or sham injections. Enrollment will be stratified in order to ensure a balance between the two treatment groups for subjects who were diagnosed with exudative AMD within the past two years versus those diagnosed more than two years prior to Baseline.

Study assessments will be conducted at required visits every three months and include manifest refraction and ETDRS visual acuity testing, slit lamp exam and dilated fundus exam, spectral-domain optical coherence tomography (SD-OCT) using Avanti device, and OCT angiography using Avanti AngioVueTM, and fluorescein angiography. Fundus photography will also be performed at Baseline, Month 12 and Month 24 visits.

In the event of conversion to neovascular AMD in the study eye at any point during the study, the Investigator will treat the subject with IAI at a frequency per his/her discretion.

Clinical Study Identifier: NCT02462889

Contact Investigators or Research Sites near you

Start Over

David S Boyer, MD

Retina-Vitreous Associates Medical Group
Beverly Hills, CA United States
  Connect »

Alison M Nowak, BBA

Ophthalmic Consultants of Boston
Boston, MA United States
  Connect »

Sumit P Shah, MD

NJ Retina
Edison, NJ United States
  Connect »

David M Brown, MD

Retina Consultants of Houston
Houston, TX United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.